Ionizable Lipid Composition for pH-Responsive Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid delivery technologies, such as cationic lipids like DODAC, DOTMA, and DOTAP, are too toxic for clinical applications, and there is a need for more clinically relevant transfection lipids to efficiently deliver genetic material to living cells.
Innovation Solution
Development of ionizable lipids with specific chemical structures and pKa values, formulated into lipid nanoparticles with defined ratios of structural lipids, stabilizing agents, and therapeutic agents, to facilitate safe and efficient delivery of nucleic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipids like DODAC, DOTMA, and DOTAP are used for nucleic acid delivery, then transfection efficiency is improved, but cell toxicity increases making them unsuitable for clinical applications
Solution Approach 1:
The patent changes the ionization state parameter of the lipid molecules by designing ionizable lipids that transition from neutral at physiological pH to cationic at endosomal pH. This allows the lipids to maintain low toxicity in circulation while becoming actively cationic only within endosomes to facilitate nucleic acid delivery, thus resolving the contradiction between transfection efficiency and cell toxicity
Solution Approach 2:
The invention introduces dynamic pH-responsive behavior to the lipid molecules, enabling them to change their charge state based on the local environment. The lipids remain neutral in the bloodstream (reducing toxicity) but become protonated and cationic within the acidic endosomal compartment (enhancing transfection), thereby dynamically adapting their properties to different physiological conditions
2Object-affected harmful factors
If ionizable lipids are developed for clinical applications, then cell toxicity is reduced, but transfection efficiency and delivery capability must be maintained or improved
Solution Approach 1:
The patent optimizes the pKa values of the ionizable lipid groups (secondary, tertiary, or quaternary amines) to ensure they remain predominantly neutral at physiological pH (minimizing toxicity) but become sufficiently cationic at endosomal pH (maintaining transfection efficiency). This parameter optimization resolves the contradiction between reduced toxicity and maintained delivery capability
Solution Approach 2:
The invention creates composite lipid structures combining hydrophobic tails with pH-responsive ionizable head groups. These composite molecules integrate the membrane-disrupting capability of traditional cationic lipids with the low toxicity of neutral lipids, achieving both reduced systemic toxicity and effective endosomal transfection
3Adaptability or versatility
If more options for clinically relevant transfection lipids are developed, then adaptability to different nucleic acid therapeutics is improved, but chemical structure complexity increases
Solution Approach 1:
The patent designs a universal platform of ionizable lipids with common structural motifs (hydrophobic tails and ionizable head groups) that can be systematically varied to create multiple clinically relevant variants. This modular approach enables adaptation to different nucleic acid therapeutics (mRNA, siRNA, DNA) while maintaining a manageable level of chemical complexity through standardized building blocks
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ionizable lipids achieve high transfection efficiency and viability of cells, enabling effective delivery of nucleic acids, including mRNA, siRNA, and polypeptides, for therapeutic and prophylactic applications, with reduced toxicity.
Implementation Method 1
ionizable lipids with specific chemical structures and pKa values
Data Source
AI summary
The present disclosure provides methods for modifying a cell. In one embodiment, the method includes: contacting the cell with a pharmaceutical composition including a nucleic acid payload encapsulated by a lipid mix composition having a compound of Formula (I), or a pharmaceutically acceptable salt thereof; and transfecting the nucleic acid payload into the cell.